<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00035178</url>
  </required_header>
  <id_info>
    <org_study_id>ARG-402</org_study_id>
    <nct_id>NCT00035178</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis</brief_title>
  <official_title>Pharmacokinetics and Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease (ESRD) Patients Undergoing Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Biotechnology Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Encysive Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The primary goals of this investigation are to provide guidance on how to dose Argatroban in&#xD;
      patients undergoing hemodialysis and to assess the safety and tolerability of Argatroban in&#xD;
      hemodialysis patients. The secondary goal of the study will be to assess the adequacy of&#xD;
      anticoagulation during hemodialysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date>November 2002</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>12</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <condition>Renal Disease, End-Stage</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Argatroban</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Basic Inclusion Criteria:&#xD;
&#xD;
          1. Patients, adult men or women who are between 21 and 75 years of age who are on&#xD;
             maintenance hemodialysis regimen for at least three (3) months prior to the study&#xD;
             start.&#xD;
&#xD;
          2. Patients who can tolerate a hemodialysis session lasting up to 9 hours.&#xD;
&#xD;
          3. Patients who can tolerate a hemodialysis treatment with blood flow rates of 300 ml per&#xD;
             minute.&#xD;
&#xD;
          4. Female volunteers who are not documented to be surgically sterile must be willing to&#xD;
             abstain from sexual intercourse during the study or be willing to use intrauterine&#xD;
             devices or 2 forms of barrier contraception for at least 7 days prior to the initial&#xD;
             dose of study medication and continuing through the completion of the study.&#xD;
&#xD;
        Basic Exclusion Criteria:&#xD;
&#xD;
          1. Any clinically relevant abnormality identified per the investigator on the screening&#xD;
             medical assessment or laboratory examination.&#xD;
&#xD;
          2. History of regular alcohol abuse.&#xD;
&#xD;
          3. Treatment with an investigational drug within 30 days.&#xD;
&#xD;
          4. History of drug allergy of clinical significance in the opinion of the investigator.&#xD;
&#xD;
          5. Currently taking warfarin or other anticoagulants.&#xD;
&#xD;
          6. Currently taking NSAIDs (with the exception of aspirin).&#xD;
&#xD;
          7. Individuals who are obese.&#xD;
&#xD;
          8. Any history of bleeding disorder.&#xD;
&#xD;
          9. Any subject with a screening resting systolic blood pressure &gt;180 mmHg and/or resting&#xD;
             diastolic blood pressure of &gt;100 mmHg unless, in the opinion of the principal&#xD;
             investigator, the blood pressures would not endanger the subject while participating&#xD;
             in this trial.&#xD;
&#xD;
         10. Concurrent uncontrolled cardiovascular, hematologic, respiratory, CNS,&#xD;
             gastrointestinal disease or chronic alcoholism.&#xD;
&#xD;
         11. Anemia defined as a hematocrit of &lt; 30 and hemoglobin &lt; 10g/dL.&#xD;
&#xD;
         12. Concurrently taking (within the past 30 days) phenytoin, cimetidine, rifampin,&#xD;
             cyclosporin or tacrolimus.&#xD;
&#xD;
         13. Known hypersensitivity to Argatroban or related compounds.&#xD;
&#xD;
         14. Significant hepatic insufficiency as defined by total bilirubin greater than 1.5 mg/dL&#xD;
             or transaminase (ALT, AST) elevations greater than 2 times the upper limit of the&#xD;
             laboratory reference range.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Chicago, Section of Nephrology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2003</verification_date>
  <study_first_submitted>May 2, 2002</study_first_submitted>
  <study_first_submitted_qc>May 2, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2002</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>ESRD</keyword>
  <keyword>End-stage renal disease</keyword>
  <keyword>Hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Argatroban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

